The European investment landscape requires greater access to specialized growth financing tailored to medtech companies. The current scarecity of niche investors results in suboptimal outcomes despite the high-quality science and development expertise in the region.

At SMA, we aim to address this gap by offering not only capital but also strategic insights, industry expertise, and access to our extensive networks. By partnering closely with our portfolio companies throughout the investment cycle, we strive for exceptional development and full market realization.

SMA targets investments that create long-term solutions to critical global health challenges. We focus on supporting technology-driven companies in the medtech sectors that have developed transformative products with the potential to improve patient outcomes and healthcare delivery. Our goal is to help these innovators succeed by providing the resources and strategic support needed to bring their solutions to key markets, so that life-changing technologies can reach the patients who need them most.

SMA is supported by both instituional and private investors who share our dedication to advacing the European medtech landscape. With SEK 1.3 billion in capital under management, SMA’s team has personally committed nearly 20% of the total fund reflecting our strong belief in our mission. More than 60% of our capital comes from well-established institutional investors, including two leading Swedish pension funds, a prominent European foundation, and a Swedish government entity, underscoring the strength and stability of our investment base.

The ability to scale globally is a key determinant for success. We seek to invest in products that can transcend local markets and have the potential to lead in their niche worldwide.

Leadership is key. We invest in teams that are strong, with the right leadership to drive growth and deliver results independently.

By pooling resources and expertise from co-investors we can maximize the impact of an investment and help the companies in out portfolio achieve their full potential.

By investing in things that matter. We believe that in addressing the needs and objectives that SMA is all about we are inherently investing in a way that optimizes ESG criteria as we are totally focused health and human quality of life We are entirely dedicated to advancing health technology for everyone.

By signing and promoting PFRI and SDGs. We believe that we as investors have a duty to act in the best long-term interests of our beneficiaries and that PRI’s six principles resonate well with SMA’s investment strategy. Also, we are taking SDGs into account as part of each investment process.